MMR vaccine in HIV-infected children - potential hazards?

By Goon P.   Cohen B.   Jin L.   Watkins R.   Tudor-Williams G.  

Vaccine, Vol. 19, Iss. 28, 2001-07 ,pp. : 3816-3819

Elsevier

Access to resources Recommend Favorite

MMR - public policy in crisis: whose tragedy?

By Stroud Laura  

Journal of Health, Organisation and Management, Vol. 19, Iss. 3, 2005-03 ,pp. : 252-260

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance

By Pebody R.G.   Gay N.J.   Hesketh L.M.   Vyse A.   Morgan-Capner P.   Brown D.W.   Litton P.   Miller E.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1134-1140

Elsevier

Access to resources Recommend Favorite

Absence of chicken myelin basic protein residues in commercial formulations of MMR vaccine

By Afzal M.A.   Pipkin P.A.   Minor P.D.  

Vaccine, Vol. 19, Iss. 4, 2000-10 ,pp. : 442-446

Elsevier

Access to resources Recommend Favorite

Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age *

By Klinge  

Vaccine, Vol. 18, Iss. 27, 2000-07 ,pp. : 3134-3140

Elsevier

Access to resources Recommend Favorite